Evidence map›Paper›PMID 32934708›Full record

ArticleOncology letters2020

Immunotyping of tumor-infiltrating lymphocytes in triple-negative breast cancer and genetic characterization.

Gabriela Sofia Gomez-Macias, Guillermo Molinar-Flores, Carlos A Lopez-Garcia, Sandra Santuario-Facio, Horacio Decanini-Arcaute, Javier Valero-Elizondo, Victor Treviño-Alvarado, Rocio Ortiz-Lopez, Antonio Dono, Eduardo Esteban-Zubero and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Journal of oncology · 2022
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Gabriela Sofia Gomez-MaciasDepartment of Pathology, Hospital San José TecSalud, Tecnológico de Monterrey, Monterrey, Nuevo León 64710, México.
Guillermo Molinar-FloresDepartment of Pathology, Hospital San José TecSalud, Tecnológico de Monterrey, Monterrey, Nuevo León 64710, México.
Carlos A Lopez-GarciaDepartment of Pathology, Hospital San José TecSalud, Tecnológico de Monterrey, Monterrey, Nuevo León 64710, México.
Sandra Santuario-FacioLaboratorio de Investigacion, Tecnologico de Monterrey, Monterrey, Nuevo León 64710, México.
Horacio Decanini-ArcauteDepartment of Pathology, Hospital Christus Muguerza of Alta Especialidad, Monterrey, Nuevo León 64060, México.
Javier Valero-ElizondoBreast Cancer Center, Hospital San José, TecSalud, Tecnológico de Monterrey, Monterrey, Nuevo León 64710, México.
Victor Treviño-AlvaradoLaboratorio de Investigacion, Tecnologico de Monterrey, Monterrey, Nuevo León 64710, México.
Rocio Ortiz-LopezLaboratorio de Investigacion, Tecnologico de Monterrey, Monterrey, Nuevo León 64710, México.
Antonio DonoVivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center at Houston, Medical School, Houston, TX 77030, USA.
Eduardo Esteban-ZuberoDepartment of Emergencies, San Pedro Hospital, Logroño, La Rioja 26006, Spain.
Moises A Alatorre-JimenezDepartment of Pediatrics, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA.
Cynthia Villarreal GarzaBreast Cancer Center, Hospital San José, TecSalud, Tecnológico de Monterrey, Monterrey, Nuevo León 64710, México.
Omar Peña-CurielBreast Cancer Center, Hospital San José, TecSalud, Tecnológico de Monterrey, Monterrey, Nuevo León 64710, México.
Servando Cardona-HuertaBreast Cancer Center, Hospital San José, TecSalud, Tecnológico de Monterrey, Monterrey, Nuevo León 64710, México.
Tecnológico de Monterrey · MXHospital San Pedro · ESSUNY Downstate Health Sciences University · USThe University of Texas Health Science Center at Houston · USUniversity of Monterrey · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-infiltrating lymphocytes (TILs) reflect the host immune response against cancer cells. Immunomodulators have been recently suggested as a novel therapeutic strategy against triple-negative breast cancer (TNBC). However, the TIL profile in TNBC has not been thoroughly investigated. In the present study, the percentage, immunophenotype and genetic profiles of TILs in pre-surgical tumor samples of patients with TNBC were evaluated prior to neoadjuvant chemotherapy (NAC). Patients diagnosed with breast cancer at Hospital San José TecSalud were consecutively and prospectively enrolled in the present study between August 2011 and August 2015. The pathological response to NAC was evaluated using the de Miller-Payne and MD Anderson Cancer Center system. TIL percentage (low, intermediate, and high) was evaluated using special hematoxylin-eosin staining on the core needle biopsies. The immunophenotype of TILs was assessed by immunohistochemistry (IHC) for CD3

Indexed as

breast cancertriple-negative breast cancertumor-infiltrating lymphocytes

Identifiers

PMID32934708
PMCPMC7471657
OpenAlexW3080863806

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.